Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for ​Parkinson's disease, the US biotech said ‌on Monday, sending its shares surging 72% in premarket tra...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。